Presented by expert speakers, our webinars will give you advance insight into topics that will be covered at the event.
Can’t make the date? Still register to receive the webinar recording afterwards.
Cell & Gene Therapy Webinar
Disruptive Technology in the ATMP Landscape
Wednesday 24 June 2020 | 10:30 UK Time
Presented by Len Pattenden, Head of Biotherapeutic Development & Drug Supply, Cancer Research UK
- Expert insight on the latest technologies in ATMP Development
- Manufacturing technologies for the future of ATMP process development
Our free webinar is for professionals involved in Cellular Therapeutics manufacturing interested in hearing about the latest technologies impacting ATMP development. This is a free event open to all, so why not register and benefit from the expertise of our speakers?
Currently the Head of Cancer Research UK GMP Biotherapeutics Development Unit. Leonard Pattenden’s pharmaceutical experience is primarily in the development of a range of biomolecules such as therapeutic blood factors and monoclonal antibodies, but he also has a track record in viral vector and virus-like molecule design, production, purification and manipulation. His current interests around lentiviral vectors are the application of synthetic biology and smaller-scale GMP continuous manufacturing strategies (scale-out) as an approach to meet clinical demand
Stochastic Optimization Approaches For CAR-T Cellular Drug Product Cryopreservation
Tuesday 30 June 2020 | 09:00 EST | 14:00 UK Time
Presented by Ta-Chun Hang, Senior Scientist, bluebird bio
- Expert insight on the cryopreservation of CAR-T products
- Overcoming challenges with cold supply chain
- Development of efficient testing and improving post-thaw properties
Our free webinar is for professionals involved in Cellular Therapeutics Development interested in hearing about CAR T Cryopreservation and storage. This is a free event open to all, so why not register and benefit from the expertise of our speakers?
Ta-Chun Hang is part of the Cellular Process Development group at bluebird bio. His team at bluebird focuses on generating functional and process understanding of HSC and CAR-T cellular drug product manufacturing processes, along with exploring new approaches to improve manufacturing platforms. Prior to bluebird bio, Ta-Chun worked on the upstream biologics process spanning early development to commercial manufacturing support. Ta-Chun received his PhD in Biological Engineering from the Massachusetts Institute of Technology (Cambridge, MA) in 2012, his B.E. in Biomedical Engineering and B.A. in Human Physiology from the University of Minnesota – Twin Cities (Minneapolis, MN) in 2005.
Cell Culture & Bioprocessing Webinar
Organoid And 3D Microphysiological Systems For The Improvement Of Pre-Clinical Safety Assessments
Friday, 21 August 2020 | 05:00 EST | 10:00 UK Time
Presented by Rhiannon David, Microphysiological Systems Scientific Lead, Clinical Pharmacology and Safety Sciences, AstraZeneca
- Human-sourced 3D organoids and microphysiological systems (MPS) provide an opportunity to generate safety and efficacy data for drug development with improved clinical relevance over more traditional 2D cell culture and animal models
- I will outline context of use of organoids and MPS at AstraZeneca and provide examples of data generated from these systems that demonstrate the utility of such models for safety assessment
Our complimentary webinar is for cell culture technology and cell line development experts interested in learning more about the latest innovations in 3D organoids and models. This is a free event open to all, so why not register and benefit from the expertise of our speakers?
Rhiannon is Scientific Lead for Microphysiological Systems (MPS) in Clinical Pharmacology and Safety Sciences at AstraZeneca, Cambridge, UK. Rhiannon received her PhD from the University of Birmingham in 2009 following which she joined the Department of Medicine at Imperial College, London, where she spent 5 years as a postdoctoral scientist, undertaking research into the genotoxicity of mixtures. During this time, Rhiannon developed an interest in novel techniques that would improve the in vivo relevance of in vitro assays. Rhiannon joined AstraZeneca in 2015 where she has led the development of a bone marrow microphysiological system for improved pre-clinical safety assessment and in 2020 was appointed Scientific Lead across all organ MPS for safety assessment.